The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Integral Diagnostics's Revenue for the
six
months ended in Dec. 2025 was A$393.5 Mil. Integral Diagnostics's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$28.9 Mil.
Hence, Integral Diagnostics's Receivables Turnover for the
six
months ended in Dec. 2025 was 13.61.
Integral Diagnostics (ASX:IDX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Integral Diagnostics Receivables Turnover Related Terms
Integral Diagnostics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDX vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a Receivables Turnover of 13.61 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Integral Diagnostics and its competitors. According to the industry distribution chart, Integral Diagnostics ranks #6 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 3%.
Is Integral Diagnostics' Receivables Turnover too high?
Integral Diagnostics' current Receivables Turnover is 13.61. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. Integral Diagnostics' value of 13.61 is 152.5% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #6 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #6 out of 203 companies for Receivables Turnover. This places Integral Diagnostics in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.39. Integral Diagnostics' value of 13.61 is 152.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Receivables Turnover of 13.61 is 152.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Receivables Turnover is 13.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.79, compared to a current price of A$2.06 — trading 26.2% below its estimated fair value. The current Receivables Turnover is 13.61 and 152.5% above the Medical Diagnostics & Research industry median of 5.39. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Receivables Turnover is 13.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.06 is trading 26.2% below its estimated GF Value™ of A$2.79.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
Receivables Turnover: 13.61
GF Value™: A$2.79 vs. price of A$2.06 (26.2% below fair value)
Industry Position: 152.5% above the Medical Diagnostics & Research median (#6 of 203)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score
Get the complete analysis for ASX:IDX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
